MindRank Secures $52 Million Series B to Advance AI Drug Discovery Platform and Phase III GLP-1RA Candidate MDR-001
MindRank, a clinical-stage AI-native drug discovery company, announced the completion of a $52 million Series...
Company
Shanghai Stexo Biotechnology Secures NMPA Clinical Approval for STX11101 Extracellular Vesicle Therapy in Acute Liver Failure
Shanghai Stexo Biotechnology Co., Ltd. announced that its proprietary extracellular vesicle drug STX11101 injection, derived...
Sino Biopharmaceutical Expands GSK Partnership to Commercialize Trelegy and Anoro Ellipta in China
Sino Biopharmaceutical Limited (HKG: 1177) announced an expanded strategic partnership with GlaxoSmithKline plc (GSK, NYSE:...
Immunocon, MabGalaxy Forge Full-Chain AI Antibody R&D Network for Bispecific Drug Development
Immunocon and MabGalaxy announced a comprehensive upgrade of their strategic cooperation, integrating artificial intelligence and...
Vertex Pharmaceuticals to Acquire Crinetics for $10B, Adding PALSONIFY and Atumelnant to Endocrine Portfolio
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) announced a definitive acquisition...
Hainan Shuangcheng Pharmaceutical Secures $10M US Licensing Deal for SC-C141 R&D Project
Hainan Shuangcheng Pharmaceutical Co., Ltd. (SHE: 002693) announced an exclusive licensing agreement with undisclosed American...
CStone Pharmaceuticals Partners with Arrotex for Sugemalimab Commercialization Across Australia and New Zealand
CStone Pharmaceuticals (HKG: 2616) announced an exclusive commercialization partnership with Arrotex Pharmaceuticals Pty Ltd, the...
Serapha Bio Secures $2B+ Base Editing Therapy Deal for AATD with YolTech and Completes $230M Merger
Serapha Bio announced a transformative series of transactions including an exclusive worldwide license from YolTech...
Alphamab Oncology, Nanolek Partner on Armocibart Hemophilia Prophylaxis for Russian and EAEU Markets
Alphamab Oncology (HKG: 9966) announced a strategic cooperation agreement with Russian biopharmaceutical company LLC Nanolek,...
TrueLab Biopharmaceutical, Bionyra Pharma Forge $985M TL1A Antibody Deal with Dual IBD Candidates
TrueLab Biopharmaceutical announced an exclusive license agreement with newly launched clinical-stage company Bionyra Pharma, granting...
Shanghai ZJ Bio-Tech Ebola Detection Kit Receives WHO Emergency Use Listing for Bundibugyo Strain
Shanghai ZJ Bio-Tech Co., Ltd. (SHA: 688317) announced that its Ebola Virus Nucleic Acid Detection...
cAMPfield Therapeutics Launches with $180M Series A to Advance Prifemilast PDE4 Inhibitor for IBD
cAMPfield Therapeutics, Inc. announced its official launch alongside the completion of a $180 million Series...
BriSTAR Immunotech Secures $28M Series C to Advance STAR-T Platform and In Vivo Technology
BriSTAR Immunotech (Beijing) Co., Ltd. announced the completion of a Series C financing round exceeding...
Formosa Pharmaceuticals, Samil Pharma Expand Partnership with APP13007 Vietnam Licensing Deal
Formosa Pharmaceuticals (TPE: 6838) announced an exclusive licensing agreement with South Korea’s Samil Pharmaceuticals, Co.,...
Carephar Pharmaceutical, Silk Road Medical Forge Central Asia Deal for Keverprazan P-CAB Innovation
Jiangsu Carephar Pharmaceutical Co., Ltd. and Silk Road Medical Technology announced a strategic cooperation agreement...
Astex Pharmaceuticals, Genentech Forge $515M Breast Cancer Small Molecule Drug Collaboration
Astex Pharmaceuticals announced an exclusive, worldwide research collaboration and license agreement with Genentech, a member...
Pyrotech Therapeutics Secures Hundreds of Millions in Pre-B Financing to Advance Pyroptosis-Targeted Immunomodulator Platforms for Cancer and Inflammatory Diseases
Pyrotech (Beijing) Biotechnology Co., Ltd. (“Pyrotech Therapeutics“) announced the completion of its Pre-B financing round,...
iRegene Therapeutics Secures RMB 260 Million Series C+ Financing to Advance iPSC-Derived Parkinson’s Disease Therapy with FDA Fast Track and RMAT Designations
iRegene Therapeutics Co., Ltd. announced the successful completion of RMB 260 million (approximately USD 36...
Sino Biopharmaceutical Submits China Marketing Application for World’s First Intra-Incisional Long-Acting Ropivacaine Analgesic
Sino Biopharmaceutical Limited (HKG: 1177) announced that its subsidiary, Beijing Tide Pharmaceutical, has submitted a...
Shaanxi Micot Enrolls First Patient in Phase Ib/II Clinical Trial of MT1002 for Acute Ischemic Stroke Treatment
Shaanxi Micot Pharmaceutical Technology Co., Ltd. (HKG: 2335) announced the successful enrollment of the first...